Alnylam Pharmaceuticals (ALNY) — insider trading
Health Care
Alnylam Pharmaceuticals (ALNY) has 26 reported SEC Form 4 insider transactions in our data, including 5 open-market sales among the most recent 26 (latest 2026-06-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Cravatt Benjamin | Director | Grant / award / vesting (derivative) | 4,393 | $0.00 | $0 | Form 4 |
| 2026-06-01 | PYOTT DAVID E I | Director | Option exercise / conversion (derivative) | 3,830 | $0.00 | $0 | Form 4 |
| 2026-06-01 | PYOTT DAVID E I | Director | Open-market sale | 17 | $302.65 | $5.1K | Form 4 |
| 2026-06-01 | PYOTT DAVID E I | Director | Open-market sale | 495 | $300.72 | $148.9K | Form 4 |
| 2026-06-01 | PYOTT DAVID E I | Director | Open-market sale | 1,222 | $299.87 | $366.4K | Form 4 |
| 2026-06-01 | PYOTT DAVID E I | Director | Open-market sale | 1,175 | $298.91 | $351.2K | Form 4 |
| 2026-06-01 | PYOTT DAVID E I | Director | Open-market sale | 921 | $297.71 | $274.2K | Form 4 |
| 2026-06-01 | PYOTT DAVID E I | Director | Option exercise / conversion | 3,830 | $0.00 | $0 | Form 4 |
| 2026-05-20 | Arbuckle Stuart A | Director | Grant / award / vesting (derivative) | 1,441 | $0.00 | $0 | Form 4 |
| 2026-05-20 | Arbuckle Stuart A | Director | Grant / award / vesting | 671 | $0.00 | $0 | Form 4 |
| 2026-05-20 | Ausiello Dennis A | Director | Grant / award / vesting (derivative) | 1,441 | $0.00 | $0 | Form 4 |
| 2026-05-20 | Ausiello Dennis A | Director | Grant / award / vesting | 671 | $0.00 | $0 | Form 4 |
| 2026-05-20 | BRANDICOURT OLIVIER | Director | Grant / award / vesting (derivative) | 1,441 | $0.00 | $0 | Form 4 |
| 2026-05-20 | BRANDICOURT OLIVIER | Director | Grant / award / vesting | 671 | $0.00 | $0 | Form 4 |
| 2026-05-20 | HAMBURG MARGARET A | Director | Grant / award / vesting (derivative) | 1,441 | $0.00 | $0 | Form 4 |
| 2026-05-20 | HAMBURG MARGARET A | Director | Grant / award / vesting | 671 | $0.00 | $0 | Form 4 |
| 2026-05-20 | KELLOGG PETER N | Director | Grant / award / vesting (derivative) | 1,441 | $0.00 | $0 | Form 4 |
| 2026-05-20 | KELLOGG PETER N | Director | Grant / award / vesting | 671 | $0.00 | $0 | Form 4 |
| 2026-05-20 | PYOTT DAVID E I | Director | Grant / award / vesting (derivative) | 1,441 | $0.00 | $0 | Form 4 |
| 2026-05-20 | PYOTT DAVID E I | Director | Grant / award / vesting | 671 | $0.00 | $0 | Form 4 |
| 2026-05-20 | Reitan Colleen F | Director | Grant / award / vesting (derivative) | 1,441 | $0.00 | $0 | Form 4 |
| 2026-05-20 | Reitan Colleen F | Director | Grant / award / vesting | 671 | $0.00 | $0 | Form 4 |
| 2026-05-20 | SCHULMAN AMY W | Director | Grant / award / vesting (derivative) | 1,802 | $0.00 | $0 | Form 4 |
| 2026-05-20 | SCHULMAN AMY W | Director | Grant / award / vesting | 838 | $0.00 | $0 | Form 4 |
| 2026-05-20 | Sigal Charles Elliott | Director | Grant / award / vesting (derivative) | 1,441 | $0.00 | $0 | Form 4 |
| 2026-05-20 | Sigal Charles Elliott | Director | Grant / award / vesting | 671 | $0.00 | $0 | Form 4 |
Ask the chat about ALNY's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Alnylam Pharmaceuticals (ALNY).
Last updated 2026-06-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.